Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia

Pediatrics

Volumn 103, Issue 3, 1999, Pages 610-618

  Banks, Beverly A ^a   Seri, Istvan ^a   Ischiropoulos, Harry ^a,b   Merrill, Jeffrey ^a   Rychik, Jack ^a   Ballard, Roberta A ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease; Clinical trial; Inhaled nitric oxide; Nitrotyrosine; Oxidant injury; Prematurity; Pulmonary hypertension

Indexed keywords

3 NITROTYROSINE; NITRIC OXIDE;

ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL OXYGEN TENSION; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INFANT; INHALATIONAL DRUG ADMINISTRATION; LUNG DYSPLASIA; MALE; OXYGEN CONSUMPTION; OXYGENATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; BRONCHOPULMONARY DYSPLASIA; FEMALE; HUMANS; INFANT, NEWBORN; MALE; NITRIC OXIDE; OXYGEN; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0033059098     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.103.3.610     Document Type: Article

References (56)

1. Ballard RA, Ballard PL, Cnaan A, et al. The North American trial of antenatal Thyrotropin releasing hormone (TRH) for the prevention of lung disease in the preterm infant. N Engl J Med. 1998;338:493-498
2. Zimmerman JJ, Farrell PM. Advances and issues in bronchopulmonary dysplasia. Curr Prob Pediatr. 1994;24:159-170
3. Overstreet DW, Jackson JC, Van Belle G, Truog WE. Estimation of mortality risk in chronically ventilated infants with bronchopulmonary dysplasia. Pediatrics. 1991;88:1153-1160
4. Singer L, Yamashita T, Lilien L, Collin M, Baley J. A longitudinal study of developmental outcome of infants with bronchopulmonary dysplasia and very low birth weight. Pediatrics. 1997;100:987-993
5. Shennan A, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirement in the neonatal period. Pediatrics. 1988;82:527-532
6. Kouyoumdjian C, Adnot S, Levame M, Eddahibi, Bousbaa H. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats. J Clin Invest. 1994;94: 578-584
7. Jones R, Zapol WM, Reid L. Pulmonary artery remodeling and pulmonary hypertension after exposure to hyperoxia for 7 days: a morphometric and hemodynamic study. Am J Physiol. 1984;117:273-298
8. Wilson WL, Mullen M, Olley PM, Rabinovitch M. Hyperoxia induced pulmonary vascular and lung abnormalities in young rats and potential for recovery. Pediatr Res. 1985;191:1059-1067
9. Dempsey EC, Badesch DB, Dobyns EL, Stenmark KR. Enhanced growth capacity of neonatal pulmonary artery smooth muscle cells in vitro: dependence on cell size, time from birth, insulin-like growth factor 1, and auto-activation of protein kinase C. J Cell Physiol. 1994;60:469-481
10. Hislop AA, Haworth SG. Pulmonary vascular damage and the development of cor pulmonale following hyaline membrane disease. Pediatr Pulmonol. 1990;9:152-161
11. Berman W, Yabek SM, Dillon T, Burstein R, Corlew S. Evaluation of infants with bronchopulmonary dysplasia using cardiac catheterization. Pediatrics. 1982;70:708-712
12. Gorenflo M, Vogel M, Obladen M. Pulmonary vascular changes in bronchopulmonary dysplasia: a clinicopathologic correlation in short- and long-term survivors. Pediatr Pathol. 1991;11:851-866
13. Abman SH, Wolfe RR, Accurso FJ, Koops BL, Bowman CM, Wiggins JW. Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia. Pediatrics. 1985;75:80-84
14. Bush A, Busst CM, Knight WB, Hislop AA, Haworth SG, Shinebourne EA. Changes in pulmonary circulation in severe bronchopulmonary dysplasia. Arch Dis Child. 1990;65:739-745
15. Goodman G, Perkin RM, Anas NG, Sperling DR, Hicks DA, Rowen M. Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr. 1988;112:67-72
16. Brownlee JR, Beekman RH, Rosenthal A. Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res. 1988;24:186-190
17. Thompson D, McCann E, Lewis K. A controlled trial of hydralazine in infants with bronchopulmonary dysplasia. Pediatr Res. 1986;20(4):443. Abstract
18. Eronen M, Pohjavuori M, Andersson S, Pesonen E, Raivio KO. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardiol. 1997;18:3-7
19. Jones K, Higenbottam T, Wallwork J. Pulmonary vasodilatation with prostacyclin in primary and secondary pulmonary hypertension. Chest. 1989,96:784-789
20. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation. 1997,95: 1479-1486
21. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full term and nearly full term infants with hypoxic respiratory failure. N Engl J Med. 1997;336:597-604
22. Roberts JD, Fineman JR, Morin FC, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med. 1997;336:605-610
23. Finer NN, Etches PC, Kamstra B, Tierney AJ, Peliowski A, Ryan CA. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: Dose response. J Pediatr. 1994;124:302-308
24. Kinsella JP, Truog WE, Walsh WF, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr. 1997;131:55-62
25. Abman SH, Griebel JL, Parker DK, Schmidt JM, Swanton D, Kinsella JP. Acute effect of inhaled nitric oxide in children with severe hypoxemic respiratory failure. J Pediatr. 1994;124:881-888
26. Leclerc F, Riou Y, Martinot A, et al. Inhaled nitric oxide for a severe respiratory syncytial virus infection in an infant with bronchopulmonary dysplasia. Intensive Care Med. 1994;20:511-512
27. Lonqvist PA, Winberg P, Lundell B, Sellden H, Olsson GL. Inhaled nitric oxide in neonates and children with pulmonary hypertension. Acta Paediatr. 1994;83:1132-1136
28. Thompson MW, Bates JN, Klein JM. Treatment of respiratory failure in an infant with bronchopulmonary dysplasia infected with the respiratory syncytial virus using inhaled nitric oxide and high frequency ventilation. Acta Paediatr. 1995;84:100-102
29. Hirani WM, Shannon DC, Kacmarek R, Hurford WE, Zapol WM. Inhaled nitric oxide in infants and children with bronchopulmonary dysplasia. Am J Respir Crit Care Med. 1996;153:A499
30. Banks BA, Seri I, Ischiropoulos H, Bridges N, Rychik J, Ballard RA. Inhaled nitric oxide (iNO) in infants with severe ventilator dependent bronchopulmonary dysplasia (BPD). Pediatr Res. 1997;41:246A
31. Haddad IY, Ischiropoulos H, Holm BA, Beckman JS, Baker JR, Matalon SI. Mechanisms of peroxynitrite induced injury to pulmonary surfactants. Am J Physiol. 1993;265:L555-L564
32. Ischiropoulos H, Zhu L, Chen J, et al. Peroxynitrite mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys. 1992;298:431-437
33. Banks BA, Ischiropoulos H, McClelland MM, Ballard PL, Ballard RA. Plasma 3-nitrotyrosine is elevated in bronchopulmonary dysplasia. Pediatrics. 1998;101:870-874
34. Ischiropoulos H, Beers MF, Ohnishi ST. Nitric oxide production and perivascular tyrosine nitration in brain following carbon monoxide poisoning in the rat. J Clin Invest. 1996;97:2260-2267
35. Notter RH, Egan EA, Kwong MS, Holm BA, Shapiro DL. Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: effects of dose, dispersion technique, and gestational age. Pediatr Res. 1985;19:569-577
36. Bland RD, Kullama LK, Day RW, Carlton DP, MacRitchie AN, Albertine KH. Nitric oxide inhalation decreases pulmonary vascular resistance in preterm lambs with evolving chronic lung disease. Pediatr Res. 1997;41: 247. Abstract
37. Potter CF, Dreshaj IA, Haxhiu MA, Stork EK, Chatburn RL, Martin RJ. Effect of exogenous and endogenous nitric oxide on the airway and tissue components of lung resistance in the newborn piglet. Pediatr Res. 1997;41:886-891
38. Dupuy PM, Shore SA, Drazen JM, Frostell C, Hill WA, Zapol WM. Bronchodilator action of inhaled nitric oxide in guinea pigs. J Clin Invest. 1992;90:421-428
39. Hogman M, Frostell CG, Hedenstrom H, Hedenstierna G. Inhalation of nitric oxide modulates adult human bronchial tone. Am Rev Resp Dis 1993;148:1474-1478
40. Pfeffer KD, Ellison G, Robertson D, Day RW. The effect of inhaled nitric oxide in pediatric asthma. Am J Respir Crit Care Med. 1996;153:747-751
41. Sanna A, Kurtansky A, Veriter C, Stanescu D. Bronchodilator effect of inhaled nitric oxide in healthy men. Am J Respir Crit Care Med. 1994; 150:1702-1704
42. Skimming JW, Bender KA, Hutchison AA, Drummond WH. Nitric oxide inhalation in infants with respiratory distress syndrome. J Pediatr. 1997;130:225-230
43. Kourembanas S. McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest. 1993;92:99-104
44. Pierce MR, Bancalari E. The role of inflammation in the pathogenesis of broncho-pulmonary dysplasia. Pediatr Pulmonol. 1995;19:371-378
45. Kinsella JP, Parker TA, Galan H, Sheridan BC, Halbower AC, Abman SH. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res. 1997;41:457-463
46. Guidot DM, Hybertson BM, Kitlowski RP, Repine JE. Inhaled NO prevents IL-1 induced neutrophil accumulation and associated acute edema in isolated rat lungs. Am J Physiol. 1996;271:L225-L229
47. George TN, Johnson KJ, Bates JN, Segar JL. The effect of inhaled nitric oxide (iNO) on bleeding time and platelet aggregation in neonates. Pediatr Res. 1997;41:150. Abstract
48. Hogman M, Frostell C, Arnberg H, Hedenstierna G. Bleeding time prolongation and nitric oxide inhalation. Lancet. 1993;341:1664-1665
49. Van Meurs KP, Rhine WD, Asselin JM, Durand DJ, and the Preemie NO Collaborative Group. Response of premature infants with severe respiratory failure to inhaled nitric oxide. Pediatr Pulmonol. 1997;24:319-323
50. Peliowski A, Finer NN, Etches PC, Tierney AJ, Ryan CA. Inhaled nitric oxide for premature infants after prolonged rupture of the membranes. J Pediatr. 1995;126:450-453
51. Freeman B. Free radical chemistry of nitric oxide: looking at the dark side. Chest. 1994;105(suppl):79S-84S
52. Sawyer DT, Valentine JS. How super is superoxide? Acta Chem Res. 1981;14:393-400
53. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys. 1991;288:481-487
54. King PA, Jamison E, Strahs D, Anderson VE, Brenowitz M. Footprinting proteins on DNA with peroxynitrous acid. Nucleic Acids Res. 1993;21: 2473-2478
55. Miles PR, Bowman L, Huffman L. Nitric oxide alters metabolism in isolated alveolar type II cells. Am J Physiol. 1996;271:L23-L30
56. Bauer M, Beckman JS, Bridges R, Fuller CM, Matalon S. Peroxynitrite inhibits sodium uptake in rat colonic membrane vesicles. Biochem Biophys Acta. 1992;1104:87-94